X0306 4 2020-12-15 0 0001703057 AbCellera Biologics Inc. ABCL 0001211060 THIEL PETER C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 2020-12-15 4 C 0 3811260 A 4702780 I See footnote Common Shares 2020-12-15 4 C 0 2477100 A 7179880 I See footnote Common Shares 2020-12-15 4 P 0 3000000 20.00 A 10179880 I See footnote Common Shares 2020-12-15 4 C 0 3343240 A 3343240 I See footnote Common Shares 2020-12-15 4 C 0 401050 A 401050 I See footnote Common Shares 2020-12-15 4 C 0 29240 A 29240 I See footnote Common Shares 2020-12-15 4 C 0 382357 A 382357 I See footnote Common Shares 2020-12-15 4 C 0 24660 A 24660 I See footnote Convertible Note 2020-12-11 4 A 0 30430000.00 30430000.00 A Common Shares 2477100 30430000.00 I See footnote Convertible Note 2020-12-11 4 A 0 4697050.00 4697050.00 A Common Shares 382357 4697050.00 I See footnote Convertible Note 2020-12-11 4 A 0 302950.00 302950.00 A Common Shares 24660 302950.00 I See footnote Series A2 Preferred Shares 2020-12-15 4 C 0 381126 0.00 D Common Shares 3811260 0 I See footnote Series A2 Preferred Shares 2020-12-15 4 C 0 334324 0.00 D Common Shares 3343240 0 I See footnote Series A2 Preferred Shares 2020-12-15 4 C 0 40105 0.00 D Common Shares 401050 0 I See footnote Series A2 Preferred Shares 2020-12-15 4 C 0 2924 0.00 D Common Shares 29240 0 I See footnote Convertible Note 2020-12-15 4 C 0 30430000.00 0.00 D Common Shares 2477100 0 I See footnote Convertible Note 2020-12-15 4 C 0 4697050.00 0.00 D Common Shares 382357 0 I See footnote Convertible Note 2020-12-15 4 C 0 302950.00 0.00 D Common Shares 24660 0 I See footnote These shares are held of record by ABE Investments LLC. The Reporting Person is the beneficial owner of ABE Investments LLC and has sole voting and investment power over the securities held by ABE Investments LLC. The Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date. These shares are held of record by The Founders Fund VII, LP ("FF-VII"). The Reporting Person is one of the managing members of The Founders Fund VII Management, LLC ("FFVIIM"), which is the general partner of FF-VII. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VII. The Reporting Person disclaims beneficial ownership over the shares held by FF-VII except to the extent of his pecuniary interest therein. These shares are held of record by The Founders Fund VII Principals Fund, LP ("FF-VIIP"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIP. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIP except to the extent of his pecuniary interest therein. These shares are held of record by The Founders Fund VII Entrepreneurs Fund, LP ("FF-VIIE"). The Reporting Person is one of the managing members of FFVIIM, which is the general partner of FF-VIIE. The Reporting Person may be deemed to have beneficial ownership over the securities held by FF-VIIE. The Reporting Person disclaims beneficial ownership over the shares held by FF-VIIE except to the extent of his pecuniary interest therein. The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 687,100 Common Shares. The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share plus 106,060 Common Shares. These shares are held of record by The Founders Fund Growth, LP ("FFG"). The Reporting Person is one of the managing members of The Founders Fund Growth Management, LLC ("FFGM"), which is the general partner of FFG. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFG. The Reporting Person disclaims beneficial ownership over the shares held by FFG except to the extent of his pecuniary interest therein. The convertible promissory note had a maturity date of October 30, 2025 and the principal amount of the convertible promissory note converted upon the closing of the IPO into Common Shares at a conversion price equal $17.00 per Common Share plus 6,840 Common Shares. These shares are held of record by The Founders Fund Growth Principals Fund, LP ("FFGP"). The Reporting Person is one of the managing members of FFGM, which is the general partner of FFGP. The Reporting Person may be deemed to have beneficial ownership over the securities held by FFGP. The Reporting Person disclaims beneficial ownership over the shares held by FFGP except to the extent of his pecuniary interest therein. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Tryn Stimart, attorney-in-fact 2020-12-17